Immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in elderly people over 85 years of age in Greece: the GREVAXIMO study.

Konstantina KontopoulouChristos Theodore NakasAlexandra AinatzoglouAthina IfantidouPaschalina NtotsiChristos KatsioulisGeorgios Papazisis

Published in: Aging clinical and experimental research (2021)

Taken together, our findings highlighted the high fold change (41.18) recorded in the titers of neutralizing antibodies after the second dose suggesting the need for its timely administration to elderly individuals.

Keyphrases

coronavirus disease
sars cov
middle aged
dengue virus
zika virus
community dwelling